NSN Co. Ltd Asset Resilience Ratio
NSN Co. Ltd asset resilience ratio. NSN Co. Ltd (031860) has an Asset Resilience Ratio of 1.86% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NSN Co. Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of NSN Co. Ltd (2006–2025)
Asset resilience ratio of NSN Co. Ltd from 2006 to 2025. This chart shows how NSN Co. Ltd's Asset Resilience Ratio has changed over time. Read NSN Co. Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down NSN Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NSN Co. Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩757.64 Million | 1.86% |
| Total Liquid Assets | ₩757.64 Million | 1.86% |
Asset Resilience Insights
- Limited Liquidity: NSN Co. Ltd maintains only 1.86% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
NSN Co. Ltd Industry Peers by Asset Resilience Ratio
Compare NSN Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Diagnósticos da América S.A
SA:DASA3 |
Diagnostics & Research | 10.42% |
|
SMO ClinPlus Co. Ltd.
SHE:301257 |
Diagnostics & Research | 15.78% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
NSN Co. Ltd Asset Resilience Ratio by Year (2006–2025)
NSN Co. Ltd asset resilience ratio by year from 2006 to 2025. The table below shows the annual Asset Resilience Ratio data for NSN Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.86% | ₩757.64 Million ≈ $513.44K |
₩40.72 Billion ≈ $27.60 Million |
-16.43pp |
| 2024-12-31 | 18.29% | ₩10.27 Billion ≈ $6.96 Million |
₩56.16 Billion ≈ $38.06 Million |
+0.80pp |
| 2023-12-31 | 17.49% | ₩11.56 Billion ≈ $7.83 Million |
₩66.08 Billion ≈ $44.78 Million |
+11.00pp |
| 2022-12-31 | 6.49% | ₩5.38 Billion ≈ $3.65 Million |
₩82.93 Billion ≈ $56.20 Million |
-12.03pp |
| 2021-12-31 | 18.52% | ₩12.02 Billion ≈ $8.14 Million |
₩64.91 Billion ≈ $43.99 Million |
-8.54pp |
| 2020-12-31 | 27.06% | ₩16.57 Billion ≈ $11.23 Million |
₩61.22 Billion ≈ $41.49 Million |
-29.13pp |
| 2019-12-31 | 56.19% | ₩38.40 Billion ≈ $26.02 Million |
₩68.33 Billion ≈ $46.31 Million |
+51.91pp |
| 2018-12-31 | 4.28% | ₩1.31 Billion ≈ $889.26K |
₩30.67 Billion ≈ $20.79 Million |
+0.75pp |
| 2017-12-31 | 3.53% | ₩1.15 Billion ≈ $778.22K |
₩32.56 Billion ≈ $22.07 Million |
-0.67pp |
| 2016-12-31 | 4.19% | ₩1.91 Billion ≈ $1.29 Million |
₩45.47 Billion ≈ $30.82 Million |
+1.13pp |
| 2015-12-31 | 3.06% | ₩1.20 Billion ≈ $813.71K |
₩39.20 Billion ≈ $26.57 Million |
+1.60pp |
| 2014-12-31 | 1.46% | ₩555.73 Million ≈ $376.61K |
₩38.09 Billion ≈ $25.81 Million |
-0.24pp |
| 2013-12-31 | 1.70% | ₩601.75 Million ≈ $407.80K |
₩35.50 Billion ≈ $24.06 Million |
-6.60pp |
| 2012-12-31 | 8.29% | ₩16.28 Billion ≈ $11.03 Million |
₩196.25 Billion ≈ $132.99 Million |
+1.21pp |
| 2011-12-31 | 7.08% | ₩12.12 Billion ≈ $8.21 Million |
₩171.11 Billion ≈ $115.96 Million |
-7.55pp |
| 2010-12-31 | 14.63% | ₩21.95 Billion ≈ $14.87 Million |
₩150.00 Billion ≈ $101.66 Million |
+3.47pp |
| 2006-12-31 | 11.17% | ₩2.59 Billion ≈ $1.76 Million |
₩23.21 Billion ≈ $15.73 Million |
-- |
About NSN Co. Ltd
DHX Company Co., Ltd. engages in biomedical and distribution businesses in South Korea. The company offers Microbiome to treat intractable skin diseases; REJURUB; and AI digital brain diagnostic device. It also purchases and distributes IT components, including graphics cards, DRAM, CPUs, high-capacity storage, and multi-purpose displays; import and distribution of cosmetics; f and b distribution… Read more